Pacira BioSciences (PCRX) Net Margin (2010 - 2026)

Pacira BioSciences' Net Margin history runs 17 years deep, the most recent figure standing at 1.64% for Q1 2026.

• In Q1 2026, Net Margin fell 120.0% year-over-year to 1.64%; the TTM figure through Mar 2026 stood at 0.7% (up 1546.0% YoY), while the FY2025 annual figure was 0.97%, up 1517.0% from the prior year.
• Net Margin was 1.64% for Q1 2026 at Pacira BioSciences, up from 0.83% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 15.2% in Q2 2023 to a low of 85.11% in Q3 2024.
• Historically, Net Margin has averaged 0.81% across 5 years, with a median of 3.03% in 2025.
• The sharpest annual moves came in 2024 and 2025: Net Margin sank 9173 bps in 2024, then surged 8813 bps in 2025.
• A 5-year view of Net Margin shows it stood at 2.11% in 2022, then surged by 551 bps to 13.72% in 2023, then slumped by 38 bps to 8.57% in 2024, then sank by 90 bps to 0.83% in 2025, then soared by 98 bps to 1.64% in 2026.
• The last three Net Margin figures came in at 1.64% (Q1 2026), 0.83% (Q4 2025), and 3.03% (Q3 2025), per Business Quant data.